- Home
- IQI vs LXRX Comparison
IQI vs LXRX Comparison
Compare IQI & LXRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
HOLD
Current Price
$1.31
Company Overview
Basic Information| Metric | IQI | LXRX |
|---|---|---|
| Founded | 1992 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 532.5M | 541.5M |
| IPO Year | N/A | 2000 |
Fundamental Metrics
Financial Performance| Metric | IQI | LXRX |
|---|---|---|
| Price | $10.06 | $1.31 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $3.23 |
| AVG Volume (30 Days) | 162.1K | ★ 1.4M |
| Earning Date | 01-01-0001 | 11-06-2025 |
| Dividend Yield | ★ 4.61% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $70,864,000.00 |
| Revenue This Year | N/A | $56.61 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 1255.21 |
| 52 Week Low | $8.05 | $0.28 |
| 52 Week High | $10.00 | $1.66 |
Technical Indicators
Market Signals| Indicator | IQI | LXRX |
|---|---|---|
| Relative Strength Index (RSI) | 55.99 | 43.02 |
| Support Level | $10.01 | $1.29 |
| Resistance Level | $10.14 | $1.48 |
| Average True Range (ATR) | 0.06 | 0.07 |
| MACD | 0.00 | -0.01 |
| Stochastic Oscillator | 68.00 | 10.53 |
Price Performance
Historical Comparison IQI
LXRX
About IQI Invesco Quality Municipal Income Trust
Invesco Quality Municipal Income Trust is a diversified, closed-end management investment company. Its investment objective is to provide current income which is exempt from federal income tax.
About LXRX Lexicon Pharmaceuticals Inc.
Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, also developing LX9851, an orally-delivered small molecule drug candidate, as a treatment for obesity and associated cardiometabolic.